Revenio Group: The worst valuation gap has already been closed
Revenio's share has risen by nearly 20% since our previous update, which means the clearest buying opportunity admits the weakness has passed. We made small adjustments to our forecasts after the CMD, but the big picture is largely unchanged. The long-term outlook is clear and our confidence in this strengthened, but in the short term there is still weaknesses ahead and considering this, the valuation (2024e EV/EBIT 20x) is close to justified levels.
Revenio Group
Revenio is a medical technology company. Within the Group, there is research and development of pressure measurement technology that is used in the treatment of a number of diseases such as glaucoma, osteoporosis, skin cancer, and asthma. Operations are held worldwide and are run via most subsidiaries, each with a business focus. The company's head office is located in Vantaa.
Read more on company pageKey Estimate Figures07.12.2023
2022 | 23e | 24e | |
---|---|---|---|
Revenue | 97.0 | 95.2 | 101.1 |
growth-% | 23.10 % | -1.82 % | 6.17 % |
EBIT (adj.) | 30.9 | 27.5 | 29.8 |
EBIT-% (adj.) | 31.84 % | 28.92 % | 29.48 % |
EPS (adj.) | 0.86 | 0.78 | 0.88 |
Dividend | 0.36 | 0.38 | 0.42 |
Dividend % | 0.93 % | 1.51 % | 1.66 % |
P/E (adj.) | 44.64 | 32.54 | 28.55 |
EV/EBITDA | 30.64 | 22.44 | 19.70 |